Haguenauer D, Welch V, Shea B, Tugwell P, Wells G
Clinical Epidemiologist, 135 Riverdale Avenue, Ottawa, Ontario, Canada, K1S-1R1.
Cochrane Database Syst Rev. 2000;2000(4):CD002825. doi: 10.1002/14651858.CD002825.
To assess the efficacy of fluoride therapy on bone loss, vertebral and non-vertebral fractures and side effects in postmenopausal women.
We searched Medline, Current Contents and the Cochrane Controlled Trial Registry up to December 1998.
Two independent reviewers selected RCTs which met predetermined inclusion criteria.
Two reviewers independently extracted data using predetermined forms and assessed the methodological quality of the trials using a validated scale. For dichotomous outcomes, relative risks (RR) were calculated and for continuous outcomes, weighted mean differences (WMD) of percentage change from baseline were calculated. Where heterogeneity existed (determined by a chi-square test) a random effects model was used.
Eleven studies (1429 subjects) met the inclusion criteria. The increase in lumbar spine bone mineral density (BMD) was found to be higher in the treatment group than in the control group with a WMD 8.1% (95%CI: 7.15,9.09) after two years of treatment and 16.1%(95%CI: 14.65,17.5) after four years. The RR for new vertebral fractures was not significant at two years [0.87 (95%CI: 0.51,1.46)] or at four years [0.9(95%CI: 0.71,1.14)]. The RR for new non-vertebral fractures was not significant at two years 1.2(95%CI: 0.68,2.1) but was increased at four years in the treated group 1.85(95%CI: 1.36,2.5), especially if used at high doses and in a non slow release form. The RR for gastrointestinal side effects was not significant at two years 2.18(95%CI: 0.86,1.21) but was increased at four years in the treated group 2.18(95%CI: 1.69,4.57) especially if fluoride was used at high doses and in a non slow release form. The number of withdrawals and dropouts was not different between treated and control groups at two and four years.
REVIEWER'S CONCLUSIONS: Although fluoride has an ability to increase BMD at lumbar spine, it does not result in a reduction of vertebral fractures. In increasing the dose of fluoride, one increases the risk of non-vertebral fracture and gastrointestinal side effects without any effect on the vertebral fracture rate.
评估氟化物疗法对绝经后女性骨质流失、椎体和非椎体骨折以及副作用的疗效。
我们检索了截至1998年12月的医学索引数据库(Medline)、《现刊目次》(Current Contents)和Cochrane对照试验注册库。
两名独立评审员选择符合预定纳入标准的随机对照试验(RCT)。
两名评审员使用预定表格独立提取数据,并使用经过验证的量表评估试验的方法学质量。对于二分法结局,计算相对风险(RR);对于连续性结局,计算自基线起百分比变化的加权平均差(WMD)。若存在异质性(通过卡方检验确定),则使用随机效应模型。
11项研究(1429名受试者)符合纳入标准。发现治疗组腰椎骨矿物质密度(BMD)的增加高于对照组,治疗两年后的WMD为8.1%(95%CI:7.15,9.09),四年后的WMD为16.1%(95%CI:14.65,17.5)。新椎体骨折的RR在两年时[0.87(95%CI:0.51,1.46)]和四年时[0.9(95%CI:0.71,1.14)]均无显著意义。新非椎体骨折的RR在两年时为1.2(95%CI:0.68,2.1)无显著意义,但在四年时治疗组增加至1.85(95%CI:1.36,2.5),尤其是高剂量且非缓释剂型使用时。胃肠道副作用的RR在两年时为2.18(95%CI:0.86,1.21)无显著意义,但在四年时治疗组增加至2.18(95%CI:1.69,4.57),尤其是高剂量且非缓释剂型使用氟化物时。两年和四年时,治疗组与对照组的退出和失访人数无差异。
尽管氟化物有增加腰椎BMD的能力,但并未降低椎体骨折发生率。增加氟化物剂量会增加非椎体骨折和胃肠道副作用的风险,而对椎体骨折率无任何影响。